Lilly Puts Down $200m To Use Dicerna's RNAi Platform For Metabolic, Neurological Diseases
Executive Summary
Dicerna CEO tells Scrip the companies talked for two years and the collaboration came together as new Lilly R&D leadership looked to add novel approaches. Milestone fees of $350m per target for 10 or more targets value the deal at $3.7bn.